Skip to main content
UniHealth

Doctor search

Michaela Liedtke, MD

Hematology · Stanford

NPI 1609918556

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Liedtke’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A86006 · Current

Licensed to practise in California · since 2004 · expires 2027-07-31 · Medical Academy of Hannover.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$119,253

Medicare paid this office $119,253 for 395 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)172$55,517$166
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$18,515$105
Return visit (30+ min)119$17,910$113
New patient visit (60+ min)33$6,440$195
Long return visit (40+ min)31$5,661$120
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)172$55,517$166
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$18,515$105
Return visit (30+ min)119$17,910$113
New patient visit (60+ min)33$6,440$195
Long return visit (40+ min)31$5,661$120
Return visit (30+ min)28$4,213$84
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,417$155
Hospital discharge day management, more than 30 minutes23$2,579$103
Short return visit (20+ min)23$2,057$86

Who their Medicare patients are

395 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 10% · Women 48% · Also on Medicaid 12% · Health risk score 2.37. Above the middle of the specialty; the typical hematology clinician is at 2.35.

Conditions among them: High blood pressure 66% · Chronic kidney disease 36% · Heart failure 34% · Coronary heart disease 27% · Atrial fibrillation 25% · Diabetes 22% · Depression 18% · Cancer 15% · COPD 11% · Dementia 5% · Stroke 5%.

The office billed $618,091, Medicare allowed $155,892 and paid $119,253; for 905 services of 15 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024395905752.37$618,091$119,253
20234081,098732.38$645,130$119,477
2022364907742.41$531,869$94,273
2021360993732.41$542,224$103,448
2020302811732.73$382,156$76,494
2019284727722.84$174,170$69,421
2018262659712.89$136,096$61,474
2017260867702.52$251,649$82,367
2016250764702.41$246,392$74,321
2015217694722.26$217,253$67,389
2014206740712.32$233,976$71,246
2013191691702.28$207,664$61,916

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Original Medicare services billed in 2023
Long return visit (40+ min)166$42,843$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes62$32,725$108
Return visit (30+ min)156$18,375$82
Initial hospital care with moderate level of medical decision making at least 75 minutes40$7,517$160
New patient visit (60+ min)40$6,217$155
Hospital discharge day management, more than 30 minutes33$3,963$104
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes27$3,064$73
Short return visit (20+ min)37$2,196$56
Hospital discharge day management, 30 minutes or less12$911$76

2022: 8 services

Original Medicare services billed in 2022
Long return visit (40+ min)149$37,748$130
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes52$20,685$91
Return visit (30+ min)134$13,796$81
New patient visit (60+ min)38$6,402$168
Initial hospital care with moderate level of medical decision making at least 75 minutes34$6,082$174
Short return visit (20+ min)50$3,207$53
Hospital discharge day management, more than 30 minutes22$2,254$98
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$1,568$65

2021: 11 services

Original Medicare services billed in 2021
Long return visit (40+ min)127$29,975$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes64$25,285$94
Return visit (30+ min)122$13,824$85
New patient visit (60+ min)54$9,158$170
Initial hospital care with moderate level of medical decision making at least 75 minutes36$7,653$182
Hospital discharge day management, more than 30 minutes44$4,903$98
Short return visit (20+ min)55$3,457$58
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes25$3,452$65
New patient visit (45+ min)12$1,517$126
Telephone medical discussion with physician, 11-20 minutes16$1,095$61
Hospital discharge day management, 30 minutes or less12$832$64

2020: 11 services

Original Medicare services billed in 2020
Long return visit (40+ min)119$22,116$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes42$20,064$97
Return visit (30+ min)72$7,103$65
Initial hospital care with moderate level of medical decision making at least 75 minutes29$6,297$180
New patient visit (60+ min)38$5,966$157
Long return visit (40+ min)31$3,493$103
Hospital discharge day management, more than 30 minutes18$2,216$101
Short return visit (20+ min)31$1,499$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,421$68
New patient visit (45+ min)13$1,371$105
Telephone medical discussion with physician, 21-30 minutes14$1,109$74

2019: 9 services

Original Medicare services billed in 2019
Long return visit (40+ min)116$21,803$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$19,432$94
Initial hospital care with moderate level of medical decision making at least 75 minutes30$6,975$184
New patient visit (60+ min)43$6,469$150
Return visit (30+ min)74$6,244$66
Hospital discharge day management, more than 30 minutes17$1,785$99
Short return visit (20+ min)31$1,764$44
New patient visit (45+ min)11$1,123$102
Hospital discharge day management, 30 minutes or less12$878$68

2018: 8 services

Original Medicare services billed in 2018
Long return visit (40+ min)131$27,603$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$11,890$94
New patient visit (60+ min)43$6,472$151
Return visit (30+ min)56$5,198$65
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,183$182
Hospital discharge day management, more than 30 minutes22$2,173$99
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,344$122
Short return visit (20+ min)20$1,106$43

2017: 9 services

Original Medicare services billed in 2017
Long return visit (40+ min)121$29,995$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes47$27,296$93
Initial hospital care with moderate level of medical decision making at least 75 minutes31$6,345$181
New patient visit (60+ min)44$6,184$141
Return visit (30+ min)50$4,159$61
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$2,397$65
Hospital discharge day management, more than 30 minutes19$1,866$98
Hospital discharge day management, 30 minutes or less12$795$66
Short return visit (20+ min)13$548$39

2016: 7 services

Original Medicare services billed in 2016
Long return visit (40+ min)131$31,232$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes42$22,930$92
New patient visit (60+ min)64$8,972$140
Initial hospital care with moderate level of medical decision making at least 75 minutes20$4,146$180
Return visit (30+ min)24$1,891$70
Hospital discharge day management, more than 30 minutes14$1,459$97
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,336$121

2015: 7 services

Original Medicare services billed in 2015
Long return visit (40+ min)107$27,594$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$22,435$93
New patient visit (60+ min)48$6,617$138
Initial hospital care with moderate level of medical decision making at least 75 minutes21$3,694$176
Return visit (30+ min)34$2,697$63
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,585$122
Hospital discharge day management, more than 30 minutes14$1,366$98

2014: 7 services

Original Medicare services billed in 2014
Long return visit (40+ min)100$27,976$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$25,644$92
New patient visit (60+ min)51$7,052$138
Initial hospital care with moderate level of medical decision making at least 75 minutes21$3,777$180
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$1,947$122
Return visit (30+ min)29$1,784$51
Hospital discharge day management, more than 30 minutes12$1,255$97

2013: 8 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$23,733$90
Long return visit (40+ min)73$18,517$92
New patient visit (60+ min)45$6,241$139
Return visit (30+ min)59$5,349$59
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,637$173
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,313$119
Hospital discharge day management, 30 minutes or less12$773$64
Short return visit (20+ min)14$552$34

Medicaid work

$6,466 in 2024

Medicaid paid $6,466 for 77 billed services this clinician did in 2024, up to 18 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)77$6,466
Medicaid work by year
202477118$6,466
2023138120$8,792
2022102117$5,817
2021185214$7,949
201912112$557
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)138$8,792

2022

Largest Medicaid services in 2022
Long return visit (40+ min)102$5,817

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES128$5,089
Long return visit (40+ min)57$2,860

2019

Largest Medicaid services in 2019
Long return visit (40+ min)12$557

Drugs they prescribed that Part D paid

$2,051,121

Pharmacies billed $2,051,121 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 356) in 2024. At or below the middle of the specialty; the typical hematology clinician is at 4%.

219 generic and fewer than 11 brand-name prescriptions · $2,051,121 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Pomalyst40$962,047$24,051
Revlimid33$590,247$17,886
Venclexta42$373,593$8,895
Acyclovir78$2,281$29
Entecavir12$997$83
See all 7 drugs
Every Part D drug this clinician prescribed
Pomalyst40$962,047$24,051
Revlimid33$590,247$17,886
Venclexta42$373,593$8,895
Acyclovir78$2,281$29
Entecavir12$997$83
Dexamethasone31$489$16
Gabapentin12$327$27

Year by year

Part D prescribing by year
2024356700% (0)None$2,051,121
2023372850% (0)None$1,621,890
202251987None37%$2,885,170
202141679None54%$3,672,307
2020400843% (12)52%$3,452,340
2019447873% (14)46%$2,810,582
2018481934% (20)None$3,450,552
2017620988% (48)39%$2,948,275
2016582868% (48)None$2,141,162
2015524697% (35)None$1,209,484
2014633825% (32)None$1,104,790
2013393595% (18)None$922,801

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 6 drugs

Part D drugs prescribed in 2023
Pomalyst39$802,562$20,579
Revlimid23$436,746$18,989
Venclexta45$307,899$6,842
Acyclovir83$3,001$36
Entecavir15$1,637$109
Dexamethasone46$466$10

2022: 9 drugs

Part D drugs prescribed in 2022
Revlimid57$1,189,140$20,862
Pomalyst64$1,138,958$17,796
Venclexta28$257,688$9,203
Sprycel11$96,269$8,752
Atovaquone11$8,091$736
Acyclovir104$2,521$24
Dexamethasone74$1,124$15
Gabapentin15$206$14
Montelukast12$50$4

2021: 7 drugs

Part D drugs prescribed in 2021
Revlimid103$2,145,886$20,834
Pomalyst66$1,123,254$17,019
Venclexta18$146,404$8,134
Acyclovir52$1,564$30
Dexamethasone41$809$20
Entecavir13$569$44
Levofloxacin11$229$21

2020: 6 drugs

Part D drugs prescribed in 2020
Revlimid85$1,627,562$19,148
Pomalyst63$1,181,421$18,753
Sprycel11$92,633$8,421
Acyclovir67$1,485$22
Dexamethasone31$627$20
Gabapentin11$155$14

2019: 6 drugs

Part D drugs prescribed in 2019
Revlimid87$1,563,488$17,971
Pomalyst48$823,879$17,164
Ninlaro17$180,267$10,604
Sprycel16$106,681$6,668
Acyclovir91$1,531$17
Dexamethasone39$893$23

2018: 6 drugs

Part D drugs prescribed in 2018
Revlimid106$1,972,443$18,608
Pomalyst51$824,286$16,162
Venclexta11$173,327$15,757
Ninlaro14$140,292$10,021
Acyclovir80$1,358$17
Dexamethasone31$661$21

2017: 12 drugs

Part D drugs prescribed in 2017
Revlimid122$1,813,211$14,862
Pomalyst33$482,870$14,632
Ninlaro20$190,145$9,507
Jakafi11$143,390$13,035
Xarelto11$4,966$451
Morphine Sulfate Er14$2,000$143
Acyclovir96$1,301$14
Duloxetine12$1,241$103
Dexamethasone33$525$16
Hydromorphone14$371$27
Allopurinol11$58$5
Lorazepam12$38$3

2016: 10 drugs

Part D drugs prescribed in 2016
Revlimid97$1,182,732$12,193
Pomalyst30$394,945$13,165
Ninlaro23$199,142$8,658
Jakafi12$131,209$10,934
Sprycel16$69,054$4,316
Morphine Sulfate Er13$2,151$165
Acyclovir104$1,155$11
Dexamethasone62$574$9
Hydromorphone15$519$35
Lorazepam15$104$7

2015: 11 drugs

Part D drugs prescribed in 2015
Revlimid55$551,679$10,031
Pomalyst29$346,473$11,947
Thalomid16$144,064$9,004
Lyrica11$3,827$348
Nexium11$2,751$250
Acyclovir67$985$15
Dexamethasone54$531$10
Hydromorphone12$318$27
Lorazepam23$183$8
Pantoprazole13$138$11
Sulfamethoxazole-Trimethoprim22$125$6

2014: 14 drugs

Part D drugs prescribed in 2014
Pomalyst53$516,829$9,751
Revlimid49$456,583$9,318
Lyrica12$3,400$283
Acyclovir82$2,127$26
Mercaptopurine12$1,342$112
Dexamethasone80$998$12
Hydrocortisone11$464$42
Gabapentin18$215$12
Sulfamethoxazole-Trimethoprim22$188$9
Pantoprazole27$184$7
Prednisone17$118$7
Amlodipine Besylate16$61$4
Furosemide12$38$3
Trazodone11$32$3

2013: 7 drugs

Part D drugs prescribed in 2013
Revlimid56$501,369$8,953
Pomalyst26$286,210$11,008
Acyclovir34$715$21
Dexamethasone45$312$7
Zolpidem14$97$7
Losartan11$93$8
Allopurinol11$57$5

Money from drug and device companies

$8,454 in 2025

Industry payments by year
202545$8,454$8,454
202433$10,912$10,912
202323$4,093$4,093
202247$11,213$12,507
202156$11,903$11,912
202069$19,019$19,019
2019427$35,851$45,336

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
E.R. Squibb & Sons L.L.C.None$2,865
1 payment
  • Consulting · 2025-08-22 · $2,865
AstraZeneca Pharmaceuticals LPNone$2,858
2 payments
  • Paid to speak or teach · 2025-10-31 · $408
  • Consulting · 2025-08-01 · $2,450
AstraZeneca UKNone$2,460
1 payment
  • Consulting · 2025-06-03 · $2,460
Taiho OncologyNone$272
1 payment
  • Paid to speak or teach · 2025-10-31 · $272
See all 5 published payments
Every published payment
AstraZeneca Pharmaceuticals LPPaid to speak or teach · 2025-10-31None$408
Taiho OncologyPaid to speak or teach · 2025-10-31None$272
E.R. Squibb & Sons L.L.C.Consulting · 2025-08-22None$2,865
AstraZeneca Pharmaceuticals LPConsulting · 2025-08-01None$2,450
AstraZeneca UKConsulting · 2025-06-03None$2,460
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $10,912

Payments by company in 2024
Alexion PharmaceuticalsNone$4,680
1 payment
  • Consulting · 2024-11-06 · $4,680
Jazz PharmaceuticalsRylaze$3,532
1 payment
  • Paid to speak or teach for Rylaze · 2024-12-24 · $3,532
AbbvieNone$2,700
1 payment
  • Consulting · 2024-01-16 · $2,700

2023: $4,093

Payments by company in 2023
E.R. Squibb & Sons L.L.C.None$3,855
2 payments
  • Consulting · 2023-02-13 · $2,076
  • Consulting · 2023-01-25 · $1,779
AstraZeneca Pharmaceuticals LPNone$238
1 payment
  • Paid to speak or teach · 2023-02-14 · $238

2022: $12,507

Payments by company in 2022
Kite PharmaTecartus$6,294
4 payments
  • Consulting for Tecartus · 2022-10-28 · $5,000
  • Travel for Tecartus · 2022-10-07 · $170
  • Travel for Tecartus · 2022-10-07 · $885
  • Travel for Tecartus · 2022-10-07 · $239
Legend Biotech USACarvykti$2,550
1 payment
  • Consulting for Carvykti · 2022-09-09 · $2,550
Adaptive BiotechnologiesClonoseq$2,400
1 payment
  • Consulting for Clonoseq · 2022-05-18 · $2,400
Janssen BiotechTecvayli$1,263
1 payment
  • Consulting for Tecvayli · 2022-12-01 · $1,263

2021: $11,912

Payments by company in 2021
Takeda Pharmaceuticals U.S.A.Exkivity$3,970
2 payments
  • Education for Iclusig · 2021-11-18 · $10
  • Consulting for Exkivity · 2021-04-02 · $3,960
Janssen BiotechDarzalex$2,525
1 payment
  • Consulting for Darzalex · 2021-07-14 · $2,525
GlaxoSmithKlineBlenrep$1,950
1 payment
  • Consulting for Blenrep · 2021-03-23 · $1,950
Janssen Scientific AffairsDarzalex$1,768
1 payment
  • Consulting for Darzalex · 2021-10-06 · $1,768
Kite PharmaTecartus$1,700
1 payment
  • Consulting for Tecartus · 2021-06-25 · $1,700

2020: $19,019

Payments by company in 2020
GlaxoSmithKlineBlenrep$5,200
4 payments
  • Consulting for Blenrep · 2020-12-14 · $1,300
  • Consulting for Blenrep · 2020-10-23 · $325
  • Consulting · 2020-09-04 · $1,950
  • Consulting · 2020-06-05 · $1,625
Alnylam PharmaceuticalsOxlumo$4,128
1 payment
  • Consulting for Oxlumo · 2020-12-15 · $4,128
GenzymeSarclisa$2,517
1 payment
  • Consulting for Sarclisa · 2020-09-14 · $2,517
CelgeneRevlimid$2,450
1 payment
  • Consulting for Revlimid · 2020-12-24 · $2,450
Kite PharmaTecartus$2,400
1 payment
  • Consulting for Tecartus · 2020-11-30 · $2,400
Karyopharm TherapeuticsXpovio$2,325
1 payment
  • Honoraria for Xpovio · 2020-12-11 · $2,325

2019: $45,336

Payments by company in 2019
PfizerBesponsa$18,360
9 payments
  • Paid to speak or teach for Besponsa · 2019-11-20 · $3,200
  • Consulting · 2019-11-11 · $4,700
  • Paid to speak or teach for Besponsa · 2019-10-21 · $780
  • Paid to speak or teach for Besponsa · 2019-09-20 · $780
  • Paid to speak or teach for Besponsa · 2019-05-20 · $3,200
  • Paid to speak or teach for Besponsa · 2019-03-27 · $940
  • Paid to speak or teach for Besponsa · 2019-01-18 · $780
  • Paid to speak or teach for Besponsa · 2019-01-14 · $780
  • Paid to speak or teach for Besponsa · 2019-01-02 · $3,200
AmgenKyprolis$15,852
3 payments
  • Travel for Kyprolis · 2019-07-26 · $6,852
  • Travel for Kyprolis · 2019-07-26 · $764
  • Paid to speak or teach for Kyprolis · 2019-07-26 · $8,236
CelgeneRevlimid$9,833
10 payments
  • Meals · 2019-12-06 · $40
  • Travel · 2019-11-13 · $91
  • Consulting · 2019-10-09 · $5,650
  • Travel · 2019-09-20 · $626
  • Meals · 2019-09-20 · $112
  • Travel · 2019-09-20 · $305
  • Travel · 2019-09-20 · $262
  • Consulting for Revlimid · 2019-07-23 · $2,600
  • Meals for Revlimid · 2019-07-19 · $26
  • Meals for Revlimid · 2019-07-19 · $121
Janssen BiotechDarzalex$1,292
5 payments
  • Meals for Darzalex · 2019-12-06 · $82
  • Meals for Darzalex · 2019-12-06 · $47
  • Travel for Darzalex · 2019-02-11 · $33
  • Consulting for Darzalex · 2019-01-30 · $1,005
  • Meals for Darzalex · 2019-01-10 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Ichnos Glenmark Innovation Inc · 2025This clinician$449,061
Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2020Their institution$353,567
Celgene Corporation · A Phase I, Multicenter, Open-Label Study of Cc-986 · 2022Their institution$334,815
Celgene Corporation · Crb-401a Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma (Crb-401) · 2019Their institution$266,254
Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2021Their institution$246,387
Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2022Their institution$193,118
Alexion Pharmaceuticals, Inc. · A Phase 2, Open Label, Multicenter Dose Selection Study To Evaluate the Safety and Tolerability of Cael 101 in Patients With Al Amyloidosis · 2024Their institution$174,220
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2024Their institution$133,975
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2023Their institution$109,988
Alexion Pharmaceuticals, Inc. · A Phase 2, Open Label, Multicenter Dose Selection Study To Evaluate the Safety and Tolerability of Cael 101 in Patients With Al Amyloidosis · 2023Their institution$102,540
Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma · 2020Their institution$94,005
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2025Their institution$90,994
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2022Their institution$88,219
PFIZER INC. · A Phase 1 Study of Seabcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2024Their institution$78,917
Celgene Corporation · Phase I Poc Dose Escalation (Cc-98633-Mm-001) - A Phase I, Multicenter, Open-Label Study of Cc-98633, Bcma Targeted Nex-T Chimeric Antigen Receptor (Car) T Cells, in Subjects With Relapsed and/Or Refractory Multiple Myeloma · 2023Their institution$71,733
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2024Their institution$59,328
AstraZeneca Pharmaceuticals LP · A Phase 1/2 Study To Evaluate the Safety and Efficacy of Azd0486 in Adolescent and Adult Participants With Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukaemia · 2025Their institution$56,859
Genentech, Inc. · Beti Multiple Myeloma Phase Ib · 2020Their institution$54,539
Takeda Pharmaceuticals U.S.A., Inc. · A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (Vxld) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia · 2019Their institution$37,049
Genentech, Inc. · Beti Multiple Myeloma Phase Ib · 2019Their institution$36,956
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2023Their institution$34,075
IGI Inc · 2024This clinician$31,892
Celgene Corporation · Phiii Ide-Cel Vs Triplet Rrmm 3l · 2020Their institution$29,536
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2019Their institution$28,759
Gilead Sciences, Inc. · A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · 2021Their institution$26,977
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2020Their institution$25,438
Celgene Corporation · Phase I Poc Dose Escalation (Cc-98633-Mm-001) - A Phase I, Multicenter, Open-Label Study of Cc-98633, Bcma Targeted Nex-T Chimeric Antigen Receptor (Car) T Cells, in Subjects With Relapsed and/Or Refractory Multiple Myeloma · 2024Their institution$25,431
Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2024Their institution$23,531
Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells. A Prospective Study for the Long-Term Follow-Up (Ltfu) of Safety and Efficacy for All Pediatric and Adult Participants Exposed To Gene-Modified (Gm) T-Cell Therapy Participating in A Previous Celgene Sponsored Or Celgene Alliance Partner Sponsored Study. · 2025Their institution$21,511
Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma · 2023Their institution$20,257
Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2023Their institution$17,293
ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2025Their institution$15,548
ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2024Their institution$13,844
Celgene Corporation · A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-221 in Subjects With Advanced Hematologic Malignancies With An Idh2 Mutation (Ag-221-C-001) · 2019Their institution$13,056
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2025Their institution$12,384
JAZZ PHARMACEUTICALS INC. · Phase III, Multicenter, Randomized, Trial of Cpx-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) Aml · 2020Their institution$12,224
Celgene Corporation · A Phase I, Multicenter, Open-Label Study of Cc-986 · 2021Their institution$10,806
JAZZ PHARMACEUTICALS INC. · Cltr0310-301 - Phase III Multicenter, Trial of Cpx-351 (Cytarabine:Daunorunbicin) Liposome Injection Vs Cytarabine Daunorunbicin in Patients 60-75 Years of Age · 2020Their institution$10,624
ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2024Their institution$8,256
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2022Their institution$7,816
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2022Their institution$7,602
PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2020This clinician$6,000
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2023Their institution$5,683
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2021Their institution$5,620
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2024Their institution$4,579
PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2023This clinician$3,200
Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma (Crb-401) · 2019This clinician$2,866
Celgene Corporation · Phase 3, Randomized, Open-Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Relapsed Or Refractory Multiple Myeloma · 2025Their institution$2,624
Janssen Research & Development, LLC · A Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared With Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2025Their institution$2,560
Celgene Corporation · A Phase 3, Multicenter, Randomized, Open-Label Stu · 2021Their institution$2,240
JAZZ PHARMACEUTICALS INC. · A Phase II Study of Cpx-351 for Treatment of Aml Or Higher Risk Mds Relapsed Or Refractory To Prior Therapy With Hypomethylating (Hma) Agent · 2020Their institution$2,240
Celgene Corporation · A Phase 3, Multicenter, Randomized, Open-Label Stu - A Phase 3, Multicenter, Randomized, Open-Label Study To Compare the Efficacy and Safety of Bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3) · 2022Their institution$2,240
ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2023Their institution$2,100
Adaptive Biotechnologies Corporation · Clonoseq · 2020Their institution$1,800
ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2022Their institution$949
Celgene Corporation · A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-221 in Subjects With Advanced Hematologic Malignancies With An Idh2 Mutation · 2020Their institution$640
Celgene Corporation · Crb-401a Phase 1 Study Ofbb2121in Bcma-Expressing Multiple Myeloma · 2021Their institution$448
PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2022This clinician$330

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1609918556
Licence
CA A86006California A86006: Current · expires 2027-07-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Medicaid ID
CA 00A860060
Taxonomy
Federal specialty code 207RH0000X (207RH0000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-02-13
NPI last updated
2024-04-12
NPI record certified
2024-04-12

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur, Stanford, CA, 94305